Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases
November 9, 2020

AXO-AAV-GM2 is the first investigational gene therapy to receive IND clearance in Tay-Sachs and Sandhoff...

Nobel Prize in Chemistry 2020: Genetic scissors: a tool for rewriting the code of life
October 13, 2020

Emmanuelle Charpentier and Jennifer Doudna are awarded the Nobel Prize in Chemistry 2020 for discovering...

Axovant and Viralgen Sign Strategic Gene Therapy Development and Manufacturing Partnership
September 15, 2020

Partnership secures access to cGMP capacity and resources at Viralgen to support the development and...

A six-month feasibility study evaluated patients’ ongoing compliance in wearing digital health technology in order to capture continuous data remotely as well as changes often missed in between hospital visits.
September 3, 2020

Abstract Background As part of a late onset GM2 gangliosidosis natural history study, digital health...

Together in Worship. The Music of Lent

Friday, February 21, 2020 at 7:30pm...

20
Feb
Blu Genes Afternoon Tea

Blu Genes is grateful to our Sponsors, supporters, friends and family for making our Afternoon...

26
May
Tay Sachs Sees Hope in First Gene Therapy Clinical Trial

Blu Genes Foundation Gives UMMS $1.4M(USD) to Bring Tay-Sachs Gene Therapy Approach to Clinical Trial...

06
Nov